BCM/TCH CHOLESTATIC LIVER DISEASE CONSORTIUM
BCM/TCH 胆汁淤积性肝病联盟
基本信息
- 批准号:10632146
- 负责人:
- 金额:$ 36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-10 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcetylcysteineAddressAdjuvant TherapyAlagille SyndromeAmericanBacterial GenesBile Acid Biosynthesis PathwayBile AcidsBile fluidBiliary AtresiaBiological MarkersChildChild HealthChildhoodCholestasisClinicalClinical DataClinical ResearchClinical TrialsCystic FibrosisDefectDevelopmentDiagnosisDiseaseDuct (organ) structureEnrollmentEtiologyEvidence based treatmentFecesFibrosisFundingGene Expression ProfileGenomicsHepatologyHourImpairmentIndividualInfantInflammatory Bowel DiseasesInterventionIntravenousInvestigationLeadLeadershipLifeLiverLiver diseasesLongitudinal StudiesMarketingMedicineMetagenomicsMethodsMitochondriaMorbidity - disease rateObservational StudyOutcomeOutcome MeasurePathogenesisPatientsPatternPediatric HospitalsPerformancePhasePilot ProjectsProgressive intrahepatic cholestasisProtocols documentationResearchResearch ActivityResearch PersonnelRoleSafetySamplingSclerosing CholangitisSerumSeverity of illnessTestingTexasTranslational ResearchUnited StatesValidationWhole-Genome Shotgun Sequencingalpha 1-Antitrypsin Deficiencyclinical centerclinical investigationclinical phenotypecollegedata repositorydisease phenotypedisease prognosisfeasibility trialfecal microbiomefollow-upgenome sequencinggut microbiomeimprovedimproved outcomeliver transplantationlongitudinal analysismetropolitanmicrobial signaturemicrobiome analysismicrobiome researchmicrobiome signaturemortalitynovelopen labelpilot trialpopulation basedprimary outcomeprimary sclerosing cholangitisprospectiveresearch studysecondary outcomestool sampletrial designwhole genome
项目摘要
Project Summary
Cholestatic liver diseases including Alagille syndrome, alpha-1 antitrypsin deficiency, bile acid synthesis
defects, biliary atresia, cystic fibrosis, mitochondrial hepatopathies, progressive familial intrahepatic cholestasis
and primary sclerosing cholangitis, lead to significant morbidity and mortality in childhood, frequently
necessitating liver transplantation. No single North American clinical center sees a large enough number of
patients with these disorders to permit a rigorous approach to addressing unresolved questions including
etiology and pathogenesis, optimal methods of diagnosis and treatment, and factors that influence disease
severity and prognosis. This competitive renewal proposal from the Baylor College of Medicine and Texas
Children's Hospital (BCM/TCH) seeks to continue ongoing research activities in the Childhood Liver Disease
Research Network (ChiLDReN). This application for renewal funding includes a strong commitment to
continuing the on-going research efforts and two new proposals, a novel pilot and feasibility clinical trial applied
to biliary atresia and a translational protocol focused on the pathogenesis of sclerosing cholangitis. The clinical
center at BCM/TCH includes an outstanding group of clinician investigators with an extensive track record in
synergistic translational and clinical research relevant to pediatric liver diseases. Performance to date in the
on-going studies of ChiLDReN has been exemplary and has taken full advantage of a predominant market
share of the population base of the Houston metropolitan region (5th largest in the United States) and the large
referral patterns to TCH as a quaternary center for Pediatric Hepatology and Liver Transplantation. A pilot and
feasibility trial of intravenous NAC will be conducted as an open label investigation in infants undergoing
hepatoportoenterstomy for biliary atresia (IND 135796 and NCT03499249). The primary outcome measure will
focus on biomarkers of bile flow. Promising findings in this pilot study could be expanded to a larger scale
multi-center investigation as part of ChiLDReN. The proposed translational protocol will use metagenomic
whole genome sequencing to assess the bacterial fecal microbiome in children with sclerosing cholangitis and
correlate microbial signatures and bacterial gene expression patterns with clinical phenotypes characterized in
the newly developed prospective observational study of primary sclerosing cholangitis in children.
项目摘要
胆汁淤积性肝病,包括Alagille综合征、α-1抗胰蛋白酶缺乏症、胆汁酸合成
缺陷、胆道闭锁、囊性纤维化、线粒体肝病、进行性家族性肝内胆汁淤积
和原发性硬化性胆管炎,导致儿童期显著的发病率和死亡率,
需要进行肝脏移植。没有一个单一的北美临床中心看到足够多的
这些疾病的患者,允许一个严格的方法来解决未解决的问题,包括
病因和发病机制,最佳诊断和治疗方法,以及影响疾病的因素
严重程度和预后。贝勒医学院和得克萨斯州的这一竞争性更新提案
儿童医院(CHN/TCH)寻求继续进行儿童肝病的研究活动
研究网络(ChiLDReN)。这一更新资金的申请包括一个坚定的承诺,
继续正在进行的研究工作和两个新的建议,一个新的试点和可行性临床试验应用
胆道闭锁和翻译协议集中在硬化性胆管炎的发病机制。临床
中心包括一组杰出的临床研究人员,他们在以下方面有着广泛的跟踪记录:
与儿科肝病相关的协同转化和临床研究迄今为止的业绩
正在进行的ChiLDReN研究堪称典范,并充分利用了主导市场
休斯顿大都市区(美国第五大)人口基数的份额和大
将TCH作为儿科肝病学和肝移植的四级中心的转诊模式。一名飞行员和
静脉注射NAC的可行性试验将作为一项开放标签研究,在接受
肝门肠吻合术治疗胆道闭锁(IND 135796和NCT 03499249)。主要结果指标将
关注胆汁流动的生物标志物。这项试验性研究中有希望的发现可以扩大到更大的规模
多中心研究作为ChiLDReN的一部分。所提出的翻译方案将使用宏基因组
全基因组测序评估硬化性胆管炎儿童的细菌粪便微生物组,
将微生物特征和细菌基因表达模式与表征为
新开发的儿童原发性硬化性胆管炎前瞻性观察研究。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Development of a Novel Tool to Assess the Impact of Itching in Pediatric Cholestasis.
- DOI:10.1007/s40271-017-0266-4
- 发表时间:2018-03
- 期刊:
- 影响因子:0
- 作者:Kamath BM;Abetz-Webb L;Kennedy C;Hepburn B;Gauthier M;Johnson N;Medendorp S;Dorenbaum A;Todorova L;Shneider BL
- 通讯作者:Shneider BL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BENJAMIN L SHNEIDER其他文献
BENJAMIN L SHNEIDER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BENJAMIN L SHNEIDER', 18)}}的其他基金
Clinical Center for ChiLDREN: Pathogenesis, Biomarkers, and Antifibrotic Therapy
ChiLDREN 临床中心:发病机制、生物标志物和抗纤维化治疗
- 批准号:
9552403 - 财政年份:2014
- 资助金额:
$ 36万 - 项目类别:
Clinical Center for ChiLDREN: Pathogenesis, Biomarkers, and Antifibrotic Therapy
ChiLDREN 临床中心:发病机制、生物标志物和抗纤维化治疗
- 批准号:
9135724 - 财政年份:2014
- 资助金额:
$ 36万 - 项目类别:
Clinical Center for ChiLDREN: Pathogenesis, Biomarkers, and Antifibrotic Therapy
ChiLDREN 临床中心:发病机制、生物标志物和抗纤维化治疗
- 批准号:
8774339 - 财政年份:2014
- 资助金额:
$ 36万 - 项目类别:
Clinical Center for ChiLDREN: Pathogenesis, Biomarkers, and Antifibrotic Therapy
ChiLDREN 临床中心:发病机制、生物标志物和抗纤维化治疗
- 批准号:
9317473 - 财政年份:2014
- 资助金额:
$ 36万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36万 - 项目类别:
Research Grant